# Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome (RLS)

> **NCT00133198** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 345 (actual)

## Conditions studied

- Restless Legs Syndrome

## Interventions

- **DRUG:** Pramipexole

## Key facts

- **NCT ID:** NCT00133198
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2005-02
- **Final completion:** 2005-02
- **Target enrollment:** 345 (ACTUAL)
- **Last updated:** 2013-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00133198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00133198, "Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome (RLS)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00133198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*